ROYALTY PHARMA PLC- CL A (RPRX) Fundamental Analysis & Valuation
NASDAQ:RPRX • GB00BMVP7Y09
Current stock price
45.53 USD
-0.26 (-0.57%)
At close:
45.53 USD
0 (0%)
After Hours:
This RPRX fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. RPRX Profitability Analysis
1.1 Basic Checks
- RPRX had positive earnings in the past year.
- RPRX had a positive operating cash flow in the past year.
- Each year in the past 5 years RPRX has been profitable.
- RPRX had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
- Looking at the Return On Assets, with a value of 3.93%, RPRX belongs to the top of the industry, outperforming 85.94% of the companies in the same industry.
- Looking at the Return On Equity, with a value of 11.90%, RPRX belongs to the top of the industry, outperforming 86.98% of the companies in the same industry.
- RPRX has a better Return On Invested Capital (6.49%) than 83.85% of its industry peers.
- RPRX had an Average Return On Invested Capital over the past 3 years of 6.59%. This is significantly below the industry average of 12.98%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.93% | ||
| ROE | 11.9% | ||
| ROIC | 6.49% |
ROA(3y)5.19%
ROA(5y)3.87%
ROE(3y)13.89%
ROE(5y)10.63%
ROIC(3y)6.59%
ROIC(5y)6.19%
1.3 Margins
- With an excellent Profit Margin value of 32.42%, RPRX belongs to the best of the industry, outperforming 95.83% of the companies in the same industry.
- RPRX's Profit Margin has improved in the last couple of years.
- With an excellent Operating Margin value of 65.58%, RPRX belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
- In the last couple of years the Operating Margin of RPRX has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 65.58% | ||
| PM (TTM) | 32.42% | ||
| GM | N/A |
OM growth 3Y16.71%
OM growth 5Y-3.47%
PM growth 3Y156.85%
PM growth 5Y6.8%
GM growth 3YN/A
GM growth 5YN/A
2. RPRX Health Analysis
2.1 Basic Checks
- The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so RPRX is destroying value.
- Compared to 1 year ago, RPRX has less shares outstanding
- RPRX has more shares outstanding than it did 5 years ago.
- Compared to 1 year ago, RPRX has a worse debt to assets ratio.
2.2 Solvency
- RPRX has an Altman-Z score of 1.81. This is not the best score and indicates that RPRX is in the grey zone with still only limited risk for bankruptcy at the moment.
- RPRX's Altman-Z score of 1.81 is fine compared to the rest of the industry. RPRX outperforms 62.50% of its industry peers.
- RPRX has a debt to FCF ratio of 11.30. This is a negative value and a sign of low solvency as RPRX would need 11.30 years to pay back of all of its debts.
- The Debt to FCF ratio of RPRX (11.30) is better than 79.17% of its industry peers.
- RPRX has a Debt/Equity ratio of 1.32. This is a high value indicating a heavy dependency on external financing.
- RPRX has a Debt to Equity ratio of 1.32. This is in the lower half of the industry: RPRX underperforms 73.96% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.32 | ||
| Debt/FCF | 11.3 | ||
| Altman-Z | 1.81 |
ROIC/WACC0.74
WACC8.76%
2.3 Liquidity
- RPRX has a Current Ratio of 2.40. This indicates that RPRX is financially healthy and has no problem in meeting its short term obligations.
- RPRX has a Current ratio (2.40) which is comparable to the rest of the industry.
- RPRX has a Quick Ratio of 2.40. This indicates that RPRX is financially healthy and has no problem in meeting its short term obligations.
- RPRX has a Quick ratio of 2.40. This is comparable to the rest of the industry: RPRX outperforms 52.08% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.4 | ||
| Quick Ratio | 2.4 |
3. RPRX Growth Analysis
3.1 Past
- RPRX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 8.05%, which is quite good.
- RPRX shows a small growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 0.60% yearly.
- The Revenue has been growing slightly by 5.06% in the past year.
- RPRX shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 2.30% yearly.
EPS 1Y (TTM)8.05%
EPS 3Y6.47%
EPS 5Y0.6%
EPS Q2Q%27.83%
Revenue 1Y (TTM)5.06%
Revenue growth 3Y2.06%
Revenue growth 5Y2.3%
Sales Q2Q%4.71%
3.2 Future
- Based on estimates for the next years, RPRX will show a quite strong growth in Earnings Per Share. The EPS will grow by 12.16% on average per year.
- The Revenue is expected to grow by 10.01% on average over the next years. This is quite good.
EPS Next Y16.65%
EPS Next 2Y11.8%
EPS Next 3Y11.89%
EPS Next 5Y12.16%
Revenue Next Year4.05%
Revenue Next 2Y4.43%
Revenue Next 3Y5.2%
Revenue Next 5Y10.01%
3.3 Evolution
- The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
- The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. RPRX Valuation Analysis
4.1 Price/Earnings Ratio
- With a Price/Earnings ratio of 10.28, the valuation of RPRX can be described as very reasonable.
- Based on the Price/Earnings ratio, RPRX is valued cheaper than 89.58% of the companies in the same industry.
- When comparing the Price/Earnings ratio of RPRX to the average of the S&P500 Index (25.73), we can say RPRX is valued rather cheaply.
- With a Price/Forward Earnings ratio of 8.81, the valuation of RPRX can be described as very reasonable.
- RPRX's Price/Forward Earnings ratio is rather cheap when compared to the industry. RPRX is cheaper than 90.63% of the companies in the same industry.
- Compared to an average S&P500 Price/Forward Earnings ratio of 23.72, RPRX is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 10.28 | ||
| Fwd PE | 8.81 |
4.2 Price Multiples
- Compared to the rest of the industry, the Price/Free Cash Flow ratio of RPRX indicates a somewhat cheap valuation: RPRX is cheaper than 79.69% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 33.16 | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- RPRX's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
- RPRX has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)0.62
PEG (5Y)17.16
EPS Next 2Y11.8%
EPS Next 3Y11.89%
5. RPRX Dividend Analysis
5.1 Amount
- RPRX has a Yearly Dividend Yield of 2.05%.
- RPRX's Dividend Yield is rather good when compared to the industry average which is at 0.77. RPRX pays more dividend than 92.71% of the companies in the same industry.
- RPRX's Dividend Yield is comparable with the S&P500 average which is at 1.91.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 2.05% |
5.2 History
- RPRX has been paying a dividend for over 5 years, so it has already some track record.
- RPRX has not decreased its dividend in the last 3 years.
Dividend Growth(5Y)N/A
Div Incr Years4
Div Non Decr Years4
5.3 Sustainability
- 49.06% of the earnings are spent on dividend by RPRX. This is a bit on the high side, but may be sustainable.
DP49.06%
EPS Next 2Y11.8%
EPS Next 3Y11.89%
RPRX Fundamentals: All Metrics, Ratios and Statistics
45.53
-0.26 (-0.57%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-11 2026-02-11/bmo
Earnings (Next)05-06 2026-05-06
Inst Owners87.31%
Inst Owner Change7.31%
Ins Owners1.59%
Ins Owner Change8.14%
Market Cap26.26B
Revenue(TTM)2.38B
Net Income(TTM)770.95M
Analysts83.75
Price Target52.39 (15.07%)
Short Float %3.08%
Short Ratio3.27
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 2.05% |
Yearly Dividend0.65
Dividend Growth(5Y)N/A
DP49.06%
Div Incr Years4
Div Non Decr Years4
Ex-Date02-20 2026-02-20 (0.235)
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)9.34%
Min EPS beat(2)8.69%
Max EPS beat(2)9.99%
EPS beat(4)3
Avg EPS beat(4)-9.55%
Min EPS beat(4)-59.9%
Max EPS beat(4)9.99%
EPS beat(8)5
Avg EPS beat(8)-3.66%
EPS beat(12)9
Avg EPS beat(12)0.82%
EPS beat(16)10
Avg EPS beat(16)-0.51%
Revenue beat(2)1
Avg Revenue beat(2)-7.72%
Min Revenue beat(2)-23.38%
Max Revenue beat(2)7.95%
Revenue beat(4)3
Avg Revenue beat(4)-0.41%
Min Revenue beat(4)-23.38%
Max Revenue beat(4)9.61%
Revenue beat(8)3
Avg Revenue beat(8)-7.18%
Revenue beat(12)3
Avg Revenue beat(12)-9.25%
Revenue beat(16)3
Avg Revenue beat(16)-10.51%
PT rev (1m)7.86%
PT rev (3m)13.89%
EPS NQ rev (1m)5.22%
EPS NQ rev (3m)4.31%
EPS NY rev (1m)-0.37%
EPS NY rev (3m)-0.36%
Revenue NQ rev (1m)96.3%
Revenue NQ rev (3m)93.91%
Revenue NY rev (1m)1.92%
Revenue NY rev (3m)4.41%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 10.28 | ||
| Fwd PE | 8.81 | ||
| P/S | 11.04 | ||
| P/FCF | 33.16 | ||
| P/OCF | 10.55 | ||
| P/B | 4.06 | ||
| P/tB | 4.73 | ||
| EV/EBITDA | N/A |
EPS(TTM)4.43
EY9.73%
EPS(NY)5.17
Fwd EY11.35%
FCF(TTM)1.37
FCFY3.02%
OCF(TTM)4.32
OCFY9.48%
SpS4.12
BVpS11.23
TBVpS9.62
PEG (NY)0.62
PEG (5Y)17.16
Graham Number33.45
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.93% | ||
| ROE | 11.9% | ||
| ROCE | 8.21% | ||
| ROIC | 6.49% | ||
| ROICexc | 7.04% | ||
| ROICexgc | 7.44% | ||
| OM | 65.58% | ||
| PM (TTM) | 32.42% | ||
| GM | N/A | ||
| FCFM | 33.31% |
ROA(3y)5.19%
ROA(5y)3.87%
ROE(3y)13.89%
ROE(5y)10.63%
ROIC(3y)6.59%
ROIC(5y)6.19%
ROICexc(3y)7.21%
ROICexc(5y)6.98%
ROICexgc(3y)7.34%
ROICexgc(5y)7.06%
ROCE(3y)8.34%
ROCE(5y)7.84%
ROICexgc growth 3Y10.47%
ROICexgc growth 5Y-5.87%
ROICexc growth 3Y8.49%
ROICexc growth 5Y-6.85%
OM growth 3Y16.71%
OM growth 5Y-3.47%
PM growth 3Y156.85%
PM growth 5Y6.8%
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.12
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.32 | ||
| Debt/FCF | 11.3 | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | 71.39% | ||
| Interest Coverage | -5.64 | ||
| Cash Conversion | N/A | ||
| Profit Quality | 102.74% | ||
| Current Ratio | 2.4 | ||
| Quick Ratio | 2.4 | ||
| Altman-Z | 1.81 |
F-Score5
WACC8.76%
ROIC/WACC0.74
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)90.64%
Cap/Sales(5y)89.1%
Profit Quality(3y)70.09%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)8.05%
EPS 3Y6.47%
EPS 5Y0.6%
EPS Q2Q%27.83%
EPS Next Y16.65%
EPS Next 2Y11.8%
EPS Next 3Y11.89%
EPS Next 5Y12.16%
Revenue 1Y (TTM)5.06%
Revenue growth 3Y2.06%
Revenue growth 5Y2.3%
Sales Q2Q%4.71%
Revenue Next Year4.05%
Revenue Next 2Y4.43%
Revenue Next 3Y5.2%
Revenue Next 5Y10.01%
EBIT growth 1Y20.66%
EBIT growth 3Y19.11%
EBIT growth 5Y-1.25%
EBIT Next Year13.04%
EBIT Next 3Y10.82%
EBIT Next 5Y10.98%
FCF growth 1Y200.85%
FCF growth 3Y25.33%
FCF growth 5YN/A
OCF growth 1Y-10.08%
OCF growth 3Y5.11%
OCF growth 5Y4.12%
ROYALTY PHARMA PLC- CL A / RPRX Fundamental Analysis FAQ
Can you provide the ChartMill fundamental rating for ROYALTY PHARMA PLC- CL A?
ChartMill assigns a fundamental rating of 6 / 10 to RPRX.
What is the valuation status for RPRX stock?
ChartMill assigns a valuation rating of 7 / 10 to ROYALTY PHARMA PLC- CL A (RPRX). This can be considered as Undervalued.
How profitable is ROYALTY PHARMA PLC- CL A (RPRX) stock?
ROYALTY PHARMA PLC- CL A (RPRX) has a profitability rating of 7 / 10.
Can you provide the PE and PB ratios for RPRX stock?
The Price/Earnings (PE) ratio for ROYALTY PHARMA PLC- CL A (RPRX) is 10.28 and the Price/Book (PB) ratio is 4.06.
Can you provide the dividend sustainability for RPRX stock?
The dividend rating of ROYALTY PHARMA PLC- CL A (RPRX) is 4 / 10 and the dividend payout ratio is 49.06%.